IDrugs and idevices discovery research: Preclinical assays, techniques, and animal model studies for ocular hypotensives and neuroprotectants

Sharif N.A.

2018
Journal of Ocular Pharmacology and Therapeutics

View publication

Therapeutic Area

Glaucoma
Technology

Drug Delivery
Categories

Disease understanding (epidemiology, diagnosis, QoL, Biomarkers…)

Affiliations

Global Alliances and External Research, Santen Incorporated, 6401 Hollis Street, Emeryville, CA 94608, United States; Department of Pharmaceutical Sciences, Texas Southern University, Houston, TX, United States; Department of Pharmacology and Neuroscience, University of North Texas Health Sciences Center, Fort Worth, TX, United States

Related Publications

Glaucomatous optic neuropathy treatment options: The promise of novel therapeutics, techniques and tools to help preserve vision

Sharif N.

Ab-Externo MicroShunt versus Trabeculectomy in Primary Open-Angle Glaucoma: 2-year Results from a Randomized, Multicenter Study

Panarelli JF, Moster MR, Garcia-Feijoo J, Flowers BE, Baker ND, Barnebey HS, Grover DS, Khatana AK, Lee B, Nguyen T, Stiles MC, Sadruddin O, Khaw PT.

Omidenepag Isopropyl in Latanoprost Low/Non-Responders with Primary Open-Angle Glaucoma or Ocular Hypertension: A Phase 3, Non-Randomized, Two-Phase, Open-Label Study

Panarelli JF, Bowden EC, Tepedino ME, Odani-Kawabata N, Pei Z, McLaurin EB, Ropo A.

View all Glaucoma publications

Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022